SCHEMBL3755198

SCHEMBL3755198

Cc1cc(C(=O)O)nn2ccnc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APOBEC3A P31941 3/20 0.49
APOBEC3G Q9HC16 2/20 0.49
RXFP1 Q9HBX9 1/20 0.39
ALDH1A1 P00352 7/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
L3MBTL1 Q9Y468 5/20 0.37
KDM4E B2RXH2 7/20 0.36
GAA P10253 4/20 0.35
POLB P06746 2/20 0.35
LMNA P02545 1/20 0.35
NAPRT Q6XQN6 1/20 0.35
P4HTM Q9NXG6 1/20 0.35
AURKA O14965 1/20 0.34
DAPK3 O43293 1/20 0.34
JAK2 O60674 1/20 0.34
MAP4K4 O95819 1/20 0.34
ABL1 P00519 1/20 0.34
NTRK1 P04629 1/20 0.34
CSF1R P07333 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26664258 0.77 RXFP1 (0.45) APOBEC3AAPOBEC3GRXFP1ALDH1A1NPC1
SCHEMBL17303162 0.75 APOBEC3A (0.48) APOBEC3AAPOBEC3GALDH1A1L3MBTL1KDM4E
SCHEMBL7893868 0.74 KDM4E (0.50) ALDH1A1NPC1RAB9AL3MBTL1KDM4E
SCHEMBL20851164 0.72 L3MBTL1 (0.41) L3MBTL1KDM4EMAPT
SCHEMBL1202772 0.72 L3MBTL1 (0.41) NPC1RAB9AL3MBTL1KDM4EMAPT
SCHEMBL31165844 0.72 KCNQ3 (0.38) KDR
SCHEMBL13050442 0.70 KDM4E (0.40) L3MBTL1KDM4ELMNAMAPT
SCHEMBL10469454 0.70 SYK (0.50) ALDH1A1NPC1RAB9AKDM4EPOLB
SCHEMBL13080151 0.69 L3MBTL1 (0.39) RXFP1ALDH1A1L3MBTL1KDM4EPOLB
SCHEMBL20272450 0.69 L3MBTL1 (0.39) NPC1RAB9AL3MBTL1KDM4ESYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150322069-A1 PHENOXYMETHYL HETEROCYCLIC COMPOUNDS FMR LLC 2015-11-12 US disclosed
US-8946222-B2 Phenoxymethyl heterocyclic compounds FORUM PHARMACEUTICALS INC. (US) 2015-02-03 US disclosed
US-20130143888-A1 PHENOXYMETHYL HETEROCYCLIC COMPOUNDS ENVIVO PHAMACEUTICALS, INC. (US) 2013-06-06 US disclosed
US-8343973-B2 Phenoxymethyl heterocyclic compounds ENVIVO PHARMACEUTICALS, INC. (US) 2013-01-01 US disclosed
US-20100292238-A1 Phenoxymethyl Heterocyclic Compounds FMR LLC 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322069-A1 PHENOXYMETHYL HETEROCYCLIC COMPOUNDS PDE3A, PDE2A, PDE5A APOBEC3A 2079/4885APOBEC3G 2264/4885RXFP1 2172/4885
US-20130143888-A1 PHENOXYMETHYL HETEROCYCLIC COMPOUNDS PDE3A, PDE2A, PDE5A APOBEC3A 2079/4885APOBEC3G 2264/4885RXFP1 2172/4885
US-20100292238-A1 Phenoxymethyl Heterocyclic Compounds PDE3A, PDE2A, PDE5A APOBEC3A 2079/4885APOBEC3G 2264/4885RXFP1 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.